tharimmune.com - נכסים נקיים למניה בודדת THAR

Tharimmune, Inc. (THAR) develops patent-protected antibodies to combat cancer, leveraging a debt-free balance sheet. However, the risk of clinical trial failure and limited capital drive volatility, which is evident in the book value per share, where the current level is 0.84. Despite this, the business remains resilient to macro cycles due to the demand for innovation and internal commercialization stages.

For the biopharmaceutical company Tharimmune, Inc. (THAR), which integrates strict ESG standards and bioethics into therapy development, the book value reflects the actual tangible asset base of the business minus liabilities. By analyzing the historical trend of the book value per share, an investor assesses the portion of net assets per security, which allows for the determination of the issuer's intrinsic value and its resilience to inflationary risks over the long term.